Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
NBRVF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume415.00
Average Volume (3M)591.00
Market Cap
$323.00
Enterprise Value-$7.19M
Total Cash (Recent Filing)$2.18M
Total Debt (Recent Filing)$540.00K
Price to Earnings (P/E)―
Beta39.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,230,837
10 Day Avg. Volume591
30 Day Avg. Volume591
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.07
P/FCF Ratio-0.07
Enterprise Value/Market Cap-22.27K
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit1.47
Enterprise Value/Ebitda0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NBRVF FAQ
What was Nabriva Therapeutics’s price range in the past 12 months?
Nabriva Therapeutics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Nabriva Therapeutics’s market cap?
Nabriva Therapeutics’s market cap is $323.00.
When is Nabriva Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nabriva Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nabriva Therapeutics overvalued?
According to Wall Street analysts Nabriva Therapeutics’s price is currently Overvalued.
Does Nabriva Therapeutics pay dividends?
Nabriva Therapeutics does not currently pay dividends.
What is Nabriva Therapeutics’s EPS estimate?
Nabriva Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nabriva Therapeutics have?
Nabriva Therapeutics has 3,230,837 shares outstanding.
What happened to Nabriva Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nabriva Therapeutics?
Currently, no hedge funds are holding shares in NBRVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nabriva Therapeutics
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
Biodexa Pharmaceuticals
―
―
Scinai Immunotherapeutics
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---